CIK 0001841387 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522214851
- Phone
- 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- 4 Grant or award Chief Technology Officer acquired 5,353 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 42,826 shares (grant or award)
- 4 Grant or award Director acquired 1,070,663 shares (grant or award)
- 4 Grant or award Director acquired 111,349 shares (grant or award)
- 4 Grant or award Director acquired 2,141 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 5,353 shares (grant or award)
- 4 Grant or award Director acquired 5,353 shares (grant or award)
- 4 Grant or award Chief Scientific Officer acquired 4,282 shares (grant or award)
- 4 Grant or award Director acquired 64,239 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 8-K Event Material agreement · Regulation FD disclosure
- 424B5 Offering Prospectus
- 8-K Event Executive or director change · Regulation FD disclosure
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 5 of 22 · 421 filings